Elevated CSF Serotonin in Prodromal Alzheimer’s Disease Patients Developing Psychosis
Journal of Dementia and Alzheimer's Disease · 13.03.2026 · 3 (1) · 14
DOI: 10.3390/jdad3010014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Dementia and Alzheimer's Disease, online erschienen am 13.03.2026. Verfasst von Victoria Monge-García und 6 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Investigación Sanitaria y Biomédica de Alicante.
Themen: Demenz
Abstract (Originalsprache)
Introduction
Psychotic symptoms (PS) in Alzheimer’s disease (AD) are associated with unfavorable prognosis, including accelerated functional decline and reduced survival. Multiple neurotransmitter systems have been implicated in the pathophysiology of PS, with the serotonergic system emerging as particularly relevant. Materials and Methods: Between 2010 and 2020, 120 patients with prodromal AD and 26 cognitively healthy controls underwent comprehensive evaluation, including clinical history, neurological and neuropsychological assessment, neuroimaging, and lumbar puncture. All participants underwent longitudinal clinical monitoring for a minimum of five years or until the emergence of PS. In February 2024, baseline cerebrospinal fluid (CSF) serotonin (5-HT) concentrations were quantified using competitive ELISA (FineTest, Wuhan, China).
Results
CSF 5-HT levels were significantly elevated (p < 0.003) in patients who subsequently developed psychosis (n = 49) compared with those who remained free of PS during the 8-year follow-up (n = 19). A threshold of 4.89 ng/mL yielded 80% sensitivity for identifying individuals at risk. Baseline Neuropsychiatric Inventory (NPI; p < 0.001) and Unified Parkinson’s Disease Rating Scale part III (UPDRS III; p < 0.009) scores also demonstrated strong discriminative capacity.
Conclusions
Measurement of CSF 5-HT and detailed clinical profiling in prodromal AD may provide predictive value for psychosis onset within 8 years of diagnosis. To our knowledge, this is the first study to report CSF 5-HT findings in AD patients.
Förderung
- Instituto de Investigación Sanitaria y Biomédica de Alicante
Zitieren
APA
Monge-García, V., Pérez-González, R., Monge-García, S., Gasparini-Berenguer, R., Sánchez-Payá, J., Silva-Afonso, R. D. F., & Monge-Argilés, J. (2026). Elevated CSF Serotonin in Prodromal Alzheimer’s Disease Patients Developing Psychosis. Journal of Dementia and Alzheimer's Disease, 3(1), 14. https://doi.org/10.3390/jdad3010014
Vancouver
Monge-García V, Pérez-González R, Monge-García S, Gasparini-Berenguer R, Sánchez-Payá J, Silva-Afonso RDF, et al. Elevated CSF Serotonin in Prodromal Alzheimer’s Disease Patients Developing Psychosis. Journal of Dementia and Alzheimer's Disease. 2026;3(1):14. doi:10.3390/jdad3010014
BibTeX
@article{MongeGarca2026,
author = {Monge-García, Victoria and Pérez-González, Rocío and Monge-García, Sonia and Gasparini-Berenguer, Ruth and Sánchez-Payá, José and Silva-Afonso, Raissa de Fátima and Monge-Argilés, José-Antonio},
title = {Elevated CSF Serotonin in Prodromal Alzheimer’s Disease Patients Developing Psychosis},
journal = {Journal of Dementia and Alzheimer's Disease},
year = {2026},
volume = {3},
number = {1},
pages = {14},
doi = {10.3390/jdad3010014}
}
EUVIMED